Chantal Fuerstner

USPTO Granted Patents = 17 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 9.3

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Muelheim An Der Ruhr, DE (2009 - 2021)
Ruhr, DE (2021)
Muelheim/Ruhr, DE (2009 - 2022)

Company Filing History:

8 out of 378

Bayer Pharma Aktiengesellschaft

patents

7 out of 53

Aicuris Gmbh + Co. Kg.

patents

4 out of 12,164

Bayer Aktiengesellschaft

patents

4. 1 out of 1

Aicuris Gmbh & Co. Hk

patent

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11331314 - Amine substituted triazole derivatives and uses thereof (2022-05-17),

2. 11298367 - Prodrugs of substituted triazole derivatives and uses thereof (2022-04-12),

3. 11230540 - Substituted triazole derivatives and uses thereof (2022-01-25),

4. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),

5. 11149023 - Substituted triazole derivatives and uses thereof (2021-10-19),

6. 11149018 - Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof (2021-10-19),

7. 11136296 - Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof (2021-10-05),

8. 11091463 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2021-08-17),

9. 10927098 - Hydroxyalkyl-substituted triazole derivatives and uses thereof (2021-02-23),

10. 7977349 - Substituted quinolones III (2011-07-12),

11. 7867992 - Substituted quinolones (2011-01-11),

12. 7786079 - Substituted nonadepsipeptides (2010-08-31),

13. 7737120 - Methods for the specific preparation of lysobactin fragments (2010-06-15),

14. 7727956 - Deoxonadepsipeptides (2010-06-01),

15. 7718611 - Cyclic nonapeptide amides (2010-05-18),

Title: Innovations by Chantal Fuerstner: A Pioneer in Triazole Derivatives

Introduction

Chantal Fuerstner, an accomplished inventor based in Muelheim/Ruhr, Germany, has cemented her reputation in the field of pharmaceutical sciences with her groundbreaking work. With a remarkable portfolio comprising 17 patents, her contributions extend to the development of novel compounds crucial for the treatment of various diseases.

Latest Patents

Fuerstner's latest innovations focus on amine substituted triazole derivatives. Her invention details processes for preparing these compounds, alongside pharmaceutical compositions that harness their potential for treating and preventing renal and cardiovascular diseases. Another notable patent revolves around the prodrugs of substituted triazole derivatives, which includes various compounds aimed at enhancing therapeutic efficacy for similar health conditions. Both patents underscore her commitment to advancing medical science through innovative research.

Career Highlights

Throughout her career, Chantal Fuerstner has made significant contributions while working with renowned organizations. She has been associated with Bayer Pharma Aktiengesellschaft and Aicuris GmbH & Co. KG, where her expertise has driven the development of critical pharmaceutical solutions. Her tenure at these companies reflects her dedication to research and product development in the pharmaceutical domain.

Collaborations

Fuerstner has collaborated with notable colleagues in the field, including Peter Kolkhof and Thomas Neubauer. These collaborations have facilitated knowledge sharing and innovation, enhancing the quality and scope of her research and inventions.

Conclusion

Chantal Fuerstner stands out as a leading inventor in the pharmaceutical industry, with her patents paving the way for new treatments. Her relentless pursuit of innovation signifies a promising future in medical research, particularly concerning renal and cardiovascular health solutions. Through her work, Fuerstner exemplifies how dedicated inventors can significantly impact global health.

This text is generated by artificial intelligence and may not be accurate.